Baker M S, Bleakley P, Woodrow G C, Doe W F
Division of Clinical Sciences, John Curtin School of Medical Research, Australian National University, Canberra.
Cancer Res. 1990 Aug 1;50(15):4676-84.
Isotopically labeled [( 3H]serine, [3H]proline, and [35S]sulfate) subendothelial cell basement membranes were used to determine the role of urokinase plasminogen activator (uPA) and its specific inhibitor plasminogen activator inhibitor 2 (PAI-2) in colon cancer cell extracellular matrix degradation. Recombinant PAI-2 irreversibly inhibited low and high molecular weight purified human uPA in addition to both colon cancer cell-associated and secreted uPA, particularly if pro-uPA had been preactivated. Two selected lines (COLO394 and LIM1215) preferentially degraded differently labeled matrices in a time- and plasminogen-dependent manner. This process was inhibitable by PAI-2 in the medium at levels which suggested that some degree of "shielding" of cell surface uPA from inhibitor occurred. The ability of PAI-2 to regulate the invasive phenotype of cells which express cell surface or receptor-bound uPA is discussed.
利用同位素标记的([³H]丝氨酸、[³H]脯氨酸和[³⁵S]硫酸盐)内皮下细胞基底膜来确定尿激酶型纤溶酶原激活剂(uPA)及其特异性抑制剂纤溶酶原激活剂抑制剂2(PAI-2)在结肠癌细胞外基质降解中的作用。重组PAI-2除了能不可逆地抑制与结肠癌细胞相关的和分泌的uPA(特别是在pro-uPA已被预激活的情况下)外,还能抑制低分子量和高分子量的纯化人uPA。两个选定的细胞系(COLO394和LIM1215)以时间和纤溶酶原依赖性方式优先降解不同标记的基质。该过程可被培养基中的PAI-2抑制,其水平表明细胞表面uPA存在一定程度的免受抑制剂“屏蔽”。本文讨论了PAI-2调节表达细胞表面或受体结合型uPA的细胞侵袭表型的能力。